Search Result

Results for "

SK-N-SH

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Adrenergic Receptor (2) Akt (1) Amyloid-β (1) Apoptosis (7) Bcl-2 Family (2) Cadherin (1) Calcium Channel (1) Caspase (3) Cytochrome P450 (1) Dopamine Receptor (2) Drug Derivative (1) Drug Metabolite (3) ERK (1) Glycosidase (1) GSK-3 (1) Histone Acetyltransferase (3) IFNAR (1) JNK (1) MDM-2/p53 (2) mTOR (1) p38 MAPK (2) PD-1/PD-L1 (1) Phosphatase (1) PROTACs (1) Reactive Oxygen Species (ROS) (2) Reference Standards (1) SARS-CoV (1) Sigma Receptor (4) Sodium Channel (1) Topoisomerase (1) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (1) Endocrinology (1) Infection (1) Metabolic Disease (1) Neurological Disease (10)

By Targets:

5-HT Receptor (2)

Adrenergic Receptor (2)

Akt (1)

Amyloid-β (1)

Apoptosis (7)

Bcl-2 Family (2)

Cadherin (1)

Calcium Channel (1)

Caspase (3)

Cytochrome P450 (1)

Dopamine Receptor (2)

Drug Derivative (1)

Drug Metabolite (3)

ERK (1)

Glycosidase (1)

GSK-3 (1)

Histone Acetyltransferase (3)

IFNAR (1)

JNK (1)

MDM-2/p53 (2)

mTOR (1)

p38 MAPK (2)

PD-1/PD-L1 (1)

Phosphatase (1)

PROTACs (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (1)

SARS-CoV (1)

Sigma Receptor (4)

Sodium Channel (1)

Topoisomerase (1)

Transmembrane Glycoprotein (1)

By Research Areas:

Cancer (14)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (1)

Metabolic Disease (1)

Neurological Disease (10)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0019

Paliperidone 3 Publications Verification 9-Hydroxyrisperidone	Drug Metabolite Dopamine Receptor 5-HT Receptor Adrenergic Receptor	Neurological Disease
Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia .

HY-P5322

Thrombospondin (TSP-1)-derived CD36 binding motif	Transmembrane Glycoprotein	Cardiovascular Disease Cancer
Thrombospondin (TSP-1)-derived CD36 binding motif is a bioactive hexapeptide. Thrombospondin (TSP-1)-derived CD36 binding motif interferes with the interaction between cells and the extracellular matrix by binding to CD36 and angiostatin, thereby affecting the cell adhesion and migration process. Thrombospondin (TSP-1)-derived CD36 binding motif inhibits platelet aggregation. Thrombospondin (TSP-1)-derived CD36 binding motif exerts an anti-tumor effect against colon cancer .

HY-B0558

Carbimazole 2 Publications Verification	p38 MAPK	Neurological Disease Endocrinology
Carbimazole is an orally active antithyroid agent which rapidly converts to Methimazole after absorption and prevents thyroid peroxidase enzyme from iodinating and coupling the tyrosine residues on thyroglobulin, hence reducing the production of thyroxine. Carbimazole also displays anti-inflammatory and neuronal-protective activities, suggesting its application for hyperthyroidism and neurological research .

HY-147288

NSC 694621 1 Publications Verification	Histone Acetyltransferase	Cancer
NSC 694621 is a potent PCAF inhibitor, with an IC₅₀ of 5.71 µM (PCAF/H3_1-21). NSC 694621 exhibits good activity of inhibiting the proliferation of cancer cells .

HY-172609

SL-176	Phosphatase Apoptosis MDM-2/p53 Caspase	Metabolic Disease Cancer
SL-176 is a PPM1D (Wip1) inhibitor. SL-176 inhibits lipid droplet formation, downregulates the mRNA and protein expression of PPARγ and C/EBPα, and blocks adipocyte differentiation. SL-176 induces G2/M cell cycle arrest, apoptosis and inhibits cell proliferation in breast cancer cells overexpressing PPM1D, and activates components of the p53 pathway. SL-176 suppresses tumor growth in a zebrafish model of neuroblastoma. SL-176 is applicable to research related to obesity, breast cancer and neuroblastoma .

HY-N8671

Withanoside V	Amyloid-β Apoptosis Reactive Oxygen Species (ROS) SARS-CoV	Infection Neurological Disease
Withanoside V is a blood-brain barrier-permeable withanolide derivative . Withanoside V binds strongly to Sudlow I (domain IIA) of human serum albumin (HSA) to form a stable complex and alter the secondary structure of albumin, thereby increasing helix content and reducing β-sheet and random coil. Withanoside V binds to Aβ (1-42) to block the interaction between monomers and subsequent aggregation. Withanoside V inhibits the viability of neuroblastoma cells, reduces the number of apoptotic cells induced by Aβ (1-42), and decreases ROS production. Withanoside V inhibits SARS-CoV-2 M_pro. Withanoside V can be used for research on Alzheimer's disease and coronavirus disease 2019 .

HY-N15314

Syringolin A	MDM-2/p53 Akt Apoptosis	Cancer
Syringolin A is a plant elicitor that can be produced by the plant pathogen Pseudomonas syringae pv. syringae. Syringolin A exhibits anti-proliferative activity against a variety of cancer cells (IC₅₀ for SK-N-SH, LAN-1, SKOV3 is 20-25 µM), induces apoptosis in SK-N-SH through upregulation of p53 expression and downregulation of Akt/PKB proteins .

HY-170405

YB-3–17	PROTACs mTOR	Cancer
YB-3-17 is a bifunctional molecule, that inhibits mTOR (IC₅₀=0.22 nM) or degrades G1 to S phase transition 1 gene (GSPT1, DC₅₀=5 nM) in a PROTAC mechanism. YB-3-17 exhibits antiproliferative activity in multi glioblastoma cell lines with IC₅₀ of nanomolare levels. YB-3-17 exhibits antitumor efficacy in mouse models . (Pink: ligand for target protein (HY-170407); Black: linker (HY-A0102); Blue: ligand for E3 ligase Cereblon (HY-14658))

HY-109583

4-Oxofenretinide 4-Oxo-4-HPR	Apoptosis Reactive Oxygen Species (ROS) Drug Metabolite	Cancer
4-Oxofenretinide (4-Oxo-4-HPR) is a metabolite of Fenretinide (HY-15373). 4-Oxofenretinide induces cell growth inhibition in ovarian, breast, and neuroblastoma tumor cell lines. 4-Oxofenretinide causes a marked accumulation of cells in G2-M. 4-Oxofenretinide induces cancer cell apoptosis through caspase-9 .

HY-175236

SF-9-2	PD-1/PD-L1 Apoptosis ERK JNK Cadherin p38 MAPK GSK-3 IFNAR Caspase Bcl-2 Family	Cancer
SF-9-2 is a PD-L1/PD-1 binding inhibitor (IC₅₀ = 24.9 nM). SF-9-2 inhibits epithelial-mesenchymal transition, migration, invasion, and proliferation of SK-N-SH cells, and also induces apoptosis and cell cycle arrest. SF-9-2 blocks PD-L1-induced SK-N-SH cell growth through the MAPK signaling pathway. SF-9-2 restores GSK-3β activity and enhances PD-L1 degradation through the ubiquitin-proteasome pathway. SF-9-2 inhibits tumor growth in the SK-N-SH NOG mouse model without significant toxicity. SF-9-2 also acts as an immune checkpoint inhibitor, blocking PD-L1 to restore T cell function. SF-9-2 can be used in neuroblastoma research .

HY-147290

NSC 694623	Histone Acetyltransferase	Cancer
NSC 694623 is a potent histone acetyltransferase (HAT) inhibitor with an IC₅₀ value of 15.9 μM for recombinant HAT p300/CBP-associated factor (PCAF). NSC 694623 has antiproliferative activity against certain cancer cells. NSC 694623 can be used for researching anticancer .

HY-119386

SAS-0132	Sigma Receptor Calcium Channel	Neurological Disease
SAS-0132 is a selective Sigma 2 receptor (Sig2R) antagonist (K_i: 90 nM) that can cross the blood-brain barrier. SAS-0132 is capable of regulating intracellular Ca ²⁺ levels and modulating PGRMC1-related pathways. SAS-0132 exhibits neuroprotective activity and can improve cognitive impairment in Alzheimer's disease mice. SAS-0132 can be used in the research of neurocognitive disorders such as Alzheimer's disease .

HY-120360

CB-64D	Sigma Receptor Apoptosis	Cancer
CB-64D is the agonist for sigma receptor 2 and sigma receptor 1 with K_i of 16.5 and 3063 nM. CB-64D induces apoptosis in cancer cell SK-N-SH .

HY-170929

EMT inhibitor-3	Bcl-2 Family Cytochrome P450 Apoptosis Caspase	Cancer
EMT inhibitor-3 (compound 11i) is a epithelial-mesenchymal transition (EMT) inhibitor. EMT inhibitor-3 inhibits neuroblastoma SK-N-SH cells with an IC₅₀ of 2.5 μM. EMT inhibitor-3 inhibits SK-N-SH cell proliferation, migration, and invasion. EMT inhibitor-3 increases the Bax/Bcl-2 protein expression ratio, promotes Cytochrome C ( HY-125857) release from mitochondria, and activates caspases 9 and caspases 3, inducing mitochondria-mediated endogenous tumor cell Apoptosis. EMT inhibitor-3 is potential for cancer research .

HY-122112

CM572	Sigma Receptor	Cancer
CM572 is a selective irreversible partial sigma-2 receptor agonist. CM572 has antitumor activity. CM572 induces dose-dependent cell death, with an EC₅₀ of 7.6 μM in SK-N-SH neuroblastoma cells. CM572 can be used for the research of kinds of diseases such as neuroblastoma, breast cancer .

HY-133195

Nefopam Fenazoxine	Sodium Channel	Neurological Disease
Nefopam (Fenazoxine) is an orally active, non-opioid and non-steroidal centrally acting analgesic agent. Nefopam blocks voltage-sensitive sodium channels (IC₅₀=27 μM) and modulates glutamatergic transmission in rodents. Nefopam can be used in studies of neuropathic pain, anticonvulsant, as well as the prevention of postoperative shivering and hiccups .

HY-118829

3,4-Methylenedioxy PV9 hydrochloride	Drug Derivative	Neurological Disease
3,4-Methylenedioxy PV9 hydrochloride is a drug derivative. 3,4-Methylenedioxy PV9 hydrochloride shows toxicity against BEAS-2B, human aortic endothelia, HASM, SK-N-SH, A172, HepG2, MKN45, and DLD1cells (LC₅₀=12.8-67.5 μM) .

HY-117420

CM764	Sigma Receptor	Cancer
CM764 is an activator for sigma receptor with K_i of 86.6 and 3.5 nM for sigma-1 receptor and sigma-2 receptor. CM764 increases cytoplasmic calcium, NAD ⁺/NADH, and ATP levels, and decreases the concentration of ROS .

HY-147289

NSC 698600	Histone Acetyltransferase	Cancer
NSC 698600 is a potent PCAF inhibitor, with IC₅₀ of 6.51 µM (PCAF/H3_1-21). NSC 698600 exhibits good activity of inhibiting the proliferation of cancer cells .

HY-A0019R

Paliperidone (Standard) 9-Hydroxyrisperidone (Standard)	Drug Metabolite Reference Standards Dopamine Receptor 5-HT Receptor Adrenergic Receptor	Neurological Disease
Paliperidone (Standard) is the analytical standard of Paliperidone. This product is intended for research and analytical applications. Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia .

HY-120679A

XK469 sodium NSC 697887 sodium	Topoisomerase	Neurological Disease Cancer
XK469 (NSC 697887) sodium is a quinoxaline-based topoisomerase II inhibitor. XK469 sodium exhibits antiproliferative activity against neuroblastoma cells. XK469 sodium can be used in the research of neuroblastoma .

HY-P11677

CPO_Aβ17-21P		Neurological Disease
CPO_Aβ17-21P is a apoE/Aβ interaction inhibitor with an IC₅₀ of 1.02 nM. CPO_Aβ17-21P significantly inhibits ApoE4-mediated aggregation of Aβ40 and Aβ42. CPO_Aβ17-21P significantly improves cognitive function and comprehensively alleviates Alzheimer's disease (AD)-related pathologies in mouse models. CPO_Aβ17-21P is applicable to the research of AD .

HY-108241A

Galacto-PUGNAc	Glycosidase	Neurological Disease
Galacto-PUGNAc is a selective competitive inhibitor of lysosomal β-hexosaminidases (HEX), with K_i values of 51 and 18 nM, for hHEXA and hHEXB, respectively. Galacto-PUGNAc elevates GM2 ganglioside levels in neuroblastoma cells. Galacto-PUGNAc can be used for the research of neurodegenerative disorders .

Cat. No.	Product Name	Target	Research Area